|Bid||4.0800 x 1800|
|Ask||4.0900 x 3100|
|Day's Range||3.9300 - 4.1300|
|52 Week Range||3.1700 - 5.4000|
|Beta (3Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Accuray Incorporated's (NASDAQ:ARAY): Accuray Incorporated designs, develops, and sells radiosurgery and radiation ther...
SUNNYVALE, Calif. , April 2, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2019 on Tuesday, April 23, 2019 after the market close. Management ...
SUNNYVALE, Calif., Feb. 22, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that data from an international, randomized, 38-center trial (PACE - Prostate Advances in Comparative Evidence) show that treatment with stereotactic body radiation therapy (SBRT) results in a similar safety profile to conventional radiation in men with low- or intermediate-risk prostate cancer. The study was presented during an oral session at the recent American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, California. SBRT involves the delivery of very high doses of externally-administered radiation over a small number of treatment sessions, offering convenience for patients, compared to conventional radiation therapy which requires a substantially longer course of treatment.
BRISBANE, Calif., Feb. 20, 2019 -- CUTERA, INC., (Nasdaq: CUTR) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Accuray Incorporated (NASDAQ:ARAY), which is in the Read More...
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Jan 28 (Reuters) - China Isotope & Radiation Corp: * ACCURAY AND CHINA ISOTOPE AND RADIATION CORPORATION ENTER JOINT VENTURE CONTRACT TO MANUFACTURE AND SELL RADIATION ONCOLOGY SYSTEMS IN CHINA * ACCURAY ...
SUNNYVALE, Calif. and TIANJIN, China, Jan. 28, 2019 /PRNewswire/ -- Accuray Asia Limited, a subsidiary of Accuray Incorporated (ARAY), and CNNC High Energy Equipment (Tianjin) Co., Ltd, a subsidiary of China Isotope and Radiation Corporation (HKSE:01763), today announced the formation of a joint venture ("JV") to manufacture and sell radiation oncology systems in China. Under the terms of the agreement, CIRC's subsidiary will own 51% of the JV and Accuray's subsidiary will own the remaining 49%.